Independent Researcher, Private Practice, Via Livigno 6, 20158 Milan, Italy.
Independent Researcher, Private Practice, Corso Monteforte 40, 20122 Milan, Italy.
Medicina (Kaunas). 2023 Nov 27;59(12):2080. doi: 10.3390/medicina59122080.
The role of the skin-gut axis in atopic dermatitis (AD) remains a subject of debate, limiting non-pharmacological interventions such as probiotics and prebiotics. To improve understanding of their potential as a monotherapy for stable mild cases, we conducted a real-life, multicenter, retrospective observational study in Italy. We administered three selected bacteria ( BS01, LP14, and LR05) orally to patients with mild atopic dermatitis without a placebo control group, following up for 12 weeks. Clinical assessments using the Scoring Atopic Dermatitis (SCORAD), Eczema Area and Severity Index (EASI), and Three-Item Severity (TIS) score were conducted on 144 enrolled patients (average age: 25.1 ± 17.6 years). Notably, both pruritus and AD-related lesions (erythema, edema/papules, excoriation) exhibited significant clinical and statistical improvement ( < 0.001) after 12 weeks of exclusive probiotic and prebiotic use. These preliminary results suggest a potential link between the skin-gut microbiome and support the rationale for using specific probiotics and prebiotics in mild AD, even for maintenance, to reduce flares and dysbiosis.
皮肤-肠道轴在特应性皮炎(AD)中的作用仍然存在争议,这限制了益生菌和益生元等非药物干预措施的应用。为了更好地了解它们作为稳定轻度病例的单一疗法的潜力,我们在意大利进行了一项真实的、多中心的、回顾性观察研究。我们给轻度特应性皮炎患者口服三种选定的细菌(BS01、LP14 和 LR05),没有安慰剂对照组,随访 12 周。对 144 名入组患者(平均年龄:25.1 ± 17.6 岁)进行了评分特应性皮炎(SCORAD)、湿疹面积和严重程度指数(EASI)和三项严重程度(TIS)评分的临床评估。值得注意的是,在单独使用益生菌和益生元 12 周后,瘙痒和与 AD 相关的病变(红斑、水肿/丘疹、抓挠)均显示出显著的临床和统计学改善(<0.001)。这些初步结果表明皮肤-肠道微生物组之间存在潜在联系,并支持在轻度 AD 中使用特定益生菌和益生元的原理,即使是维持治疗,以减少发作和微生态失调。